基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
PD-L1 表达与 TIL（肿瘤浸润淋巴细胞）浓度和组织学类型的关系及其与三阴性乳腺癌结局的关联
英文原题：Association of Programmed Death-Ligand 1 Expression in Relation to Tumor-Infiltrating Lymphocyte Concentration and Histological Type with Outcomes of Triple-Negative Breast Cancer.
查看英文原题
Association of Programmed Death-Ligand 1 Expression in Relation to Tumor-Infiltrating Lymphocyte Concentration and Histological Type with Outcomes of Triple-Negative Breast Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
TIL-H 患者的 PD-L1 阳性率更高。
中文摘要
背景
三阴性乳腺癌（TNBC）包含不同特征和组织学类型的亚组。TIL（肿瘤浸润淋巴细胞）浓度及程序性死亡配体1（PD-L1）表达是TNBC的预后因素。我们分析免疫细胞PD-L1表达与组织学类型、TIL浓度的关联及其与TNBC结局的关系。
方法
分析2008年至2014年间接受治疗的86例TNBC患者数据。排除接受免疫检查点抑制剂（ICI）治疗者。使用SP142克隆进行免疫组织化学检测免疫细胞PD-L1表达；通过苏木精-伊红染色测量TIL浓度。肿瘤组织学分为基底样型（G1）、大汗腺型（G2）、化生型（G3）、特殊类型（G4）和腺样囊性癌（G5）。
结果
TIL浓度低（TIL-L）、中等（TIL-M）和高（TIL-H）的患者中，PD-L1阳性率分别为2.5%、17.3%和58.6%（p<0.0001）。PD-L1阳性肿瘤患者5年总生存率（OS）为78.8%，阴性患者为81.8%。TIL-L患者中，PD-L1阳性和阴性肿瘤的5年OS率分别为100%和77.4%（p=0.9993）；TIL-H患者中分别为73.0%和83.3%（p=0.8241）。多变量分析显示，肿瘤大小和淋巴管侵犯是OS的独立预后因素。
结论
TIL-H患者的PD-L1阳性率较高。TIL-H且PD-L1阳性的患者TNBC结局较差。
展开英文摘要原文
BACKGROUND
Triple-negative breast cancer (TNBC) comprises subgroups with distinct characteristics and histological types. Tumor-infiltrating lymphocyte (TIL) concentration and programmed death-ligand 1 (PD-L1) expression are prognostic factors for TNBC. We analyzed the association of immune cell PD-L1 expression, in relation to histological type and TIL concentration, with TNBC outcomes.
METHODS
Data from 86 patients with TNBC treated between 2008 and 2014 were analyzed. Those treated with immune-checkpoint inhibitors (ICIs) were excluded. PD-L1 expression in immune cells was assessed by immunohistochemistry using an SP142 clone. TIL concentration was measured with hematoxylin and eosin staining. Tumor histology was classified as basal type (G1), apocrine type (G2), metaplastic change (G3), special type (G4), and adenoid cystic carcinoma (G5).
RESULTS
The rate of PD-L1 positivity was 2.5%, 17.3%, and 58.6% for patients with TIL concentrations classified as low (TIL-L), moderate (TIL-M), and high (TIL-H) (p < 0.0001). Five-year overall survival (OS) was 78.8% among patients with PD-L1-positive tumors and 81.8% among those with PD-L1-negative tumors. Among TIL-L patients, 5-year OS in PD-L1-positive and -negative tumors was 100% and 77.4%, respectively (p = 0.9993). Among TIL-H patients, 5-year OS for PD-L1-positive and -negative tumors was 73.0% and 83.3%, respectively (p = 0.8241). In multivariate analysis, tumor size and lymphatic vessel invasion were independent prognostic factors for OS.
CONCLUSIONS
The rate of PD-L1 positivity was higher in TIL-H patients. Patients classified as TIL-H and PD-L1-positive had worse TNBC outcomes.
论文信息
- 作者
- Yukawa H、Hirano A、Ishibashi Y、Fujita S、Kodera A、Anzai Y、Kurosumi M
- 单位
- Department of Breast Surgery, Tokyo Women's Medical University Adachi Medical Center.Japan
- 期刊
- Journal of Nippon Medical School = Nippon Ika Daigaku zasshi2025
- 原文标识
- PubMed 40903297 · DOI 10.1272/jnms.JNMS.2025_92-405